ABSTRACT
One hundred two patients aged 2-43 years diagnosed with acute malaria due to P. falciparum or P. vivax were treated with 3 doses of halofantrine (500 mg for > or = 18 year old patients and 8 mg/kg of patient body weight for 2-17 year olds), with each dose administered once in 6 hours and followed up for 28 days. Out of 102 patients 63 had P. falciparum, 36 had P. vivax and 3 had unidentified species. Following three dose therapy, 96.1% (98/102) of patients were cured, 0.98% (1/102) showed improvement from baseline, 1.96% (2/102) did not respond and were considered as treatment failures and one patient had indeterminate data. The lone patient, who relapsed after 120 hours post dose 1, was cured following re-treatment on day 7. The median parasite clearance and fever clearance times, from the first dose, were 26 hours and 30 hours, respectively. Eleven point eight percent (12/102) of patients reported adverse events, of which abdominal pain, reported by one subject, was considered to be probably related to the drug and required corrective therapy. There were no serious adverse events or fatalities and none of the patients had a change in QTc interval greater than 10%. Thirteen point seven percent (14/102) of patients had abnormal clinical laboratory parameters that normalized later.
Subject(s)
Adolescent , Adult , Blood Cell Count , Blood Chemical Analysis , Child , Child, Preschool , Electrocardiography , Female , Humans , Malaria, Falciparum/drug therapy , Malaria, Vivax/drug therapy , Male , Pakistan , Parasitemia , Phenanthrenes/therapeutic use , Treatment OutcomeABSTRACT
Os AA. referem o resultado do tratamento da malária falciparum, da malária vivax e da malária mista com o uso do halofantrine em esquema de dois dias de administraçäo da droga, com intervalo de cinco a sete dias entre cada um dos esquemas. Controles parasitológicos negativos foram observados em 96,6 por cento dos casos entre o 5§ e o 7§ dias pós-tratamento inicial, em 100 por cento dos casos no 14§ dia e em 84,5 por cento dos casos no 30§ dia de observaçäo. A droga mostrou-se de excelente tolerabilidade, alta praticidade de administraçäo, näo tendo sido observados efeitos colaterais no grupo controle
Subject(s)
Humans , Antimalarials/therapeutic use , Malaria, Falciparum/drug therapy , Malaria, Vivax/drug therapy , Phenanthrenes/therapeutic use , Phenanthrenes/administration & dosage , Phenanthrenes/pharmacology , Plasmodium falciparum/drug effects , Plasmodium vivax/drug effectsSubject(s)
Antimalarials/therapeutic use , Child , Child, Preschool , Female , Humans , Infant , Malaria/drug therapy , Male , Phenanthrenes/therapeutic useABSTRACT
The antimalarial efficacy of halofantrine was compared with mefloquine in an open-label, randomized comparative trial in adult male patients with acute uncomplicated falciparum malaria. Twenty-eight patients received halofantrine and 27 received mefloquine. Halofantrine was administered in 3 doses of 500 mg at 6 hour intervals and mefloquine was administered in divided doses of 1,250 mg or 1,500 mg depending on whether the patients weighed less than or more than 60 kg. The patients were followed for 42 days and observed for drug tolerance and evidence of recrudescence. Response to treatment was favorable with both drugs, but three patients (two treated with halofantrine and one with mefloquine) did not completely eliminate malaria parasites from peripheral blood films in seven days. The parasite and fever clearance times were 75.6 and 55.7 hours, and 80.1 and 61.3 hours, respectively for halofantrine and mefloquine. However, 12 patients recrudesced during the 42 day follow-up period. Nine of these had been treated with halofantrine and three with mefloquine. The 42-day cure rate for the two drugs was 56% and 84%, respectively. The side-effects of halofantrine and mefloquine were comparable and transient. These are diarrhea, dizziness, orthostatic hypotension and black out. However, vomiting was found to be more common in mefloquine group (41% vs 22%).